Equities Analysts Offer Predictions for Blueprint Medicines Co.’s Q1 2025 Earnings (NASDAQ:BPMC)

Blueprint Medicines Co. (NASDAQ:BPMC) – Stock analysts at Wedbush issued their Q1 2025 earnings per share estimates for Blueprint Medicines in a research note issued on Thursday, May 2nd. Wedbush analyst D. Nierengarten expects that the biotechnology company will post earnings of ($0.93) per share for the quarter. Wedbush currently has a “Outperform” rating and a $110.00 target price on the stock. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($5.38) per share. Wedbush also issued estimates for Blueprint Medicines’ Q2 2025 earnings at ($0.75) EPS, Q3 2025 earnings at ($0.61) EPS and Q4 2025 earnings at ($0.43) EPS.

A number of other research firms also recently commented on BPMC. HC Wainwright lifted their target price on Blueprint Medicines from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday. Piper Sandler lifted their target price on Blueprint Medicines from $78.00 to $104.00 and gave the stock a “neutral” rating in a report on Friday. JMP Securities lifted their target price on Blueprint Medicines from $114.00 to $125.00 and gave the stock a “market outperform” rating in a report on Friday. StockNews.com raised Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday. Finally, Barclays lifted their target price on Blueprint Medicines from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Friday. Three investment analysts have rated the stock with a sell rating, four have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $94.87.

Blueprint Medicines Trading Up 0.2 %

Blueprint Medicines stock opened at $107.19 on Monday. The company has a quick ratio of 3.66, a current ratio of 3.76 and a debt-to-equity ratio of 1.60. Blueprint Medicines has a 52 week low of $43.89 and a 52 week high of $110.93. The company has a market capitalization of $6.56 billion, a price-to-earnings ratio of -22.28 and a beta of 0.65. The stock has a 50-day moving average price of $91.77 and a 200 day moving average price of $80.73.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.04) by $0.22. Blueprint Medicines had a negative return on equity of 215.07% and a negative net margin of 102.15%. The business had revenue of $71.96 million for the quarter, compared to analyst estimates of $67.34 million. During the same quarter in the previous year, the firm earned ($2.65) earnings per share. The company’s revenue was up 85.5% on a year-over-year basis.

Insider Activity

In other news, Director Jeffrey W. Albers sold 25,073 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $87.28, for a total value of $2,188,371.44. Following the completion of the sale, the director now directly owns 176,050 shares in the company, valued at $15,365,644. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Jeffrey W. Albers sold 25,073 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $87.28, for a total value of $2,188,371.44. Following the completion of the sale, the director now directly owns 176,050 shares in the company, valued at $15,365,644. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Michael Landsittel sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $95.00, for a total value of $475,000.00. Following the sale, the chief financial officer now owns 47,286 shares of the company’s stock, valued at $4,492,170. The disclosure for this sale can be found here. Insiders sold 92,289 shares of company stock worth $8,314,163 over the last three months. 3.88% of the stock is currently owned by corporate insiders.

Institutional Trading of Blueprint Medicines

Large investors have recently made changes to their positions in the company. Compass Wealth Management LLC purchased a new stake in shares of Blueprint Medicines during the fourth quarter worth approximately $69,000. PNC Financial Services Group Inc. grew its holdings in Blueprint Medicines by 63.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 329 shares in the last quarter. Van ECK Associates Corp grew its holdings in Blueprint Medicines by 28.4% in the 4th quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 193 shares in the last quarter. Cutler Group LLC CA grew its holdings in Blueprint Medicines by 1,685.7% in the 3rd quarter. Cutler Group LLC CA now owns 1,000 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 944 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Blueprint Medicines in the 4th quarter valued at $95,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.